Species Differences in Drug Metabolism

Abstract

INTRODUcrIONThe importance of species differences in drug metabolism in understand ing the mechanism of action of many drugs has become increasingly evi dent. Several reviews and articles on the overall topic of drug metabolism have covered aspects of it (1-17). In addition, discussion of species differ ences in drug metabolism formed an important segment of a recent sympo sium, the proceedings of which contain a number of very informative papers (18)(19)(20)(21)(22)(23)(24).It would appear that the increasing interest in the subject stems from the premise that improved understanding and broader knowledge of species differences in drug metabolism will greatly improve our abilities to predict the pharmacologic and toxic010gic properties of a given compound in man from experimental data obtained in animals. It should also be pointed out that such studies, even when only indirectly reIated to drug therapy, have yielded valuable new biochemical information of quite fundamental nature. Examples of this type concern acetyl CoA, the role of pyridine nucleotides in oxygen incorporation, mechanisms of enzyme adaptation, human genetics, phylogenetic and ontogenetic enzyme development, intracellular structure, organ and membrane function, and biosynthesis of vitamin C (25). The in creased interest is also probably correlated with recent technological adv ances that will possibly enable one to study the physiological disposition and metabolic fate of a compound in several species within a relatively short pe riod of time.If the above comments sound encouraging, they may also be unduly opti mistic, at least insofar as prediction is concerned. For example, Williams (19) stated that aromatic hydroxylation varies quantitatively and qualita tively in haphazard fashion among species, and that one can not, at present, draw definite conclusions about the relationship between drugs, species, and metabolic routes. Brodie (23) is equally discouraging in another sense, namely, the possibility of discovering an animal species, that, drug-metabo lism-wise, is greatly similar to man. It should be pointed out here, however, that very little work of this type has been done with the higher nonhuman primates, i.e., the chimpanzee, gorilla, and orang-utan. The reader should also beware of the catchall name "monkey"since in many papers it refers to 99 Annu. Rev. Pharmacol. 1970.10:99-118. Downloaded from www.annualreviews.org Access provided by University of New South Wales on 08/14/15. For personal use only.Quick links to online content Further ANNUAL REVIEWS

Recent Progress in Hepatocyte Culture Models and Their Application to the Assessment of Drug Metabolism, Transport, and Toxicity in Drug Discovery: The Value of Tissue Engineering for the Successful Development of a Microphysiological System

“…This methodology is based on a fundamental understanding of species differences in the DMPK profile of molecules. 2 These efforts are believed to have contributed to a reduction of the attrition rate of phase-I studies in the period from 1991 to 2000 caused by issues in pharmacokinetics or bioavailability. 3 The next obstacle to overcome in clinical trials is improving the attrition rates of phase-II studies caused by safety or lack of efficacy.…”

Recent advances in soluble decellularized extracellular matrix for heart tissue engineering and organ modeling

“…[33][34][35] For instance, some drugs were found ineffective or toxic in animal models in the specified dosing therapy, whereas they are effective and safe for humans, and such differences in drug responses often hinder the research and development path. 36 Therefore, it is crucial to develop predictive and physiologically relevant preclinical models to recapitulate the tissue and disease phenotypes for screening novel drugs.…”

Engineered tissues and strategies to overcome challenges in drug development

“…As a straightforward example of this, some drugs within given dosing regimens are found to be ineffective or toxic in animal models but would be effective and safe in humans. Aspirin is illustrative of this, as it is toxic in several animal models at doses well-tolerated and effective in humans [ 41 , 42 ]. Additionally, simplistic preclinical models that insufficiently capture human disease mechanisms can hinder more complex forms of drug discovery.…”